All In Biotech

Drug Trial Radar · NCT07474792

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Mar 19, 2026

Primary completion

Oct 2027

Study completion Apr 2029

Sponsor

Lead sponsor
Oruka Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • ORKA-002Drug

    ORKA-002 administered by subcutaneous (SC) injection

  • PlaceboOther

    Placebo administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Time frame: Week 16
  2. Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse events (TEAEs) and TEAEs of of Special Interest (TEAESIs)Time frame: Day 1 through Week 48

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • Oruka Therapeutics Investigative Site

    Birmingham, Alabama

  • Oruka Therapeutics Investigative Site

    Phoenix, Arizona

  • Oruka Therapeutics Investigative Site

    Fountain Valley, California

  • Oruka Therapeutics Investigative Site

    Los Angeles, California

  • Oruka Therapeutics Investigative Site

    San Diego, California

  • Oruka Therapeutics Investigative Site

    Santa Ana, California

  • Oruka Therapeutics Investigative Site

    Santa Monica, California

  • Oruka Therapeutics Investigative Site

    Cromwell, Connecticut

  • Oruka Therapeutics Investigative Site

    Miami, Florida

  • Oruka Therapeutics Investigative Site

    Rolling Meadows, Illinois

  • Oruka Therapeutics Investigative Site

    Boston, Massachusetts

  • Oruka Therapeutics Investigative Site

    Milford, Massachusetts

  • Oruka Therapeutics Investigative Site

    Ann Arbor, Michigan

  • Oruka Therapeutics Investigative Site

    Detroit, Michigan

  • Oruka Therapeutics Investigative Site

    Warren, Michigan

  • Oruka Therapeutics Investigative Site

    New Brighton, Minnesota

  • Oruka Therapeutics Investigative Site

    Omaha, Nebraska

  • Oruka Therapeutics Investigative Site

    Elmhurst, New York

  • Oruka Therapeutics Investigative Site

    New York, New York

  • Oruka Therapeutics Investigative Site

    Wilmington, North Carolina

  • Oruka Therapeutics Investigative Site

    Bexley, Ohio

  • Oruka Therapeutics Investigative Site

    Portland, Oregon

  • Oruka Therapeutics Investigative Site

    Warrenton, Oregon

  • Oruka Therapeutics Investigative Site

    Charleston, South Carolina

  • Oruka Therapeutics Investigative Site

    Dallas, Texas

  • Oruka Therapeutics Investigative Site

    Dallas, Texas

  • Oruka Therapeutics Investigative Site

    Houston, Texas

  • Oruka Therapeutics Investigative Site

    Webster, Texas

  • Oruka Therapeutics Investigative Site

    Mill Creek, Washington

  • Oruka Therapeutics Investigative Site

    Edmonton, Alberta, Canada

  • Oruka Therapeutics Investigative Site

    Edmonton, Alberta, Canada

  • Oruka Therapeutics Investigative Site

    Surrey, British Columbia, Canada

  • Oruka Therapeutics Investigative Site

    Barrie, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    London, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    North Bay, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Peterborough, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Toronto, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Toronto, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Waterloo, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.